Patent application number | Description | Published |
20080200676 | Process for the synthesis of CMHTP and intermediates thereof - The present invention provides 3-benzyloxy-2-aminopyridine (BOPA), 3-(2-Hydroxyethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (HMBP), 3-(2-Chloroethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMHP) and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]- pyrimidin-4-one (CMHTP) useful as intermediates for the preparation of paliperidone. The present invention also provides processes for preparing these intermediates and for preparing paliperidone. | 08-21-2008 |
20080214809 | Process for the synthesis of CMHTP and intermediates thereof - The present invention provides processes of preparing 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one (CMHTP) useful as intermediates for the preparation of paliperidone, wherein the processes use 3-(2-chloroethyl)-2-methyl-9-benzyloxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMBP) and/or 3-(2-chloroethyl)-2-methyl-9-hydroxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMHP) having phosphorus at least partially removed as the intermediate. | 09-04-2008 |
20080287519 | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide - The invention encompasses amorphous eletriptan hydrobromide, processes for preparing it and pharmaceutical compositions of it. The invention also relates to processes for preparing other forms of eletriptan hydrobromide such as Form α and Form β. | 11-20-2008 |
20090012182 | Crystal forms of O-desmethylvenlafaxine succinate - Provided are crystalline forms of O-desmethylvenlafaxine succinate, methods for their preparation, and pharmaceutical composition thereof. | 01-08-2009 |
20090170948 | Crystal forms of O-desmethylvenlafaxine fumarate - Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof. | 07-02-2009 |
20090209757 | Processes for the preparation and purification of paliperidone palmitate - The present invention encompasses processes for the preparation and purification of paliperidone palmitate. | 08-20-2009 |
20090221595 | Crystalline form of sitagliptin - A Sitagliptin crystalline form characterized by PXRD pattern having any 5 peaks selected from the group consisting of 7.4, 11.5, 16.7, 17.7, 18.9, 24.1, 24.5, 27.0, 28.5 and 28.8±0.2 degrees 2-theta, wherein any combination of peaks selected includes the peak at 7.4±0.2 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided. | 09-03-2009 |
20090234125 | Amorphous retapamulin and processes for preparation thereof - An amorphous form of Retapamulin, preferably in powder form, and processes for preparation thereof, are provided. Amorphous Retapamulin of the present invention can contain less than about 10 percent crystallinity, preferably less than about 5 percent crystallinity. Pharmaceutical compositions comprising amorphous Retapamulin are also provided. | 09-17-2009 |
20090270620 | Processes for preparing crystal forms of 9-hydroxy-risperidone (paliperidone) - The present invention is related to processes for the preparation of paliperidone crystalline Form II. The invention also provides a paliperidone crystalline Form II containing isopropyl alcohol, and processes for preparing the same. | 10-29-2009 |
20100041885 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE - A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided. | 02-18-2010 |